NVCR NASDAQ
Novocure Ltd
1W: -3.3%
1M: -9.1%
3M: -11.7%
YTD: +9.8%
1Y: +3.5%
3Y: -2.8%
5Y: -87.0%
$14.62
+0.23 (+1.56%)
Weekly Expected Move ±7.0%
$13
$14
$15
$16
$17
Credit Risk of going bust: higher than 67% of companies Debt: 12.2% of company value Bonds: none of note held by US funds details ▾
If the stock fell to about $0.25 (down 98%), Novocure Ltd would be worth roughly what it owes.
Total debt $233.4M against a stock market value of $1.68B.
Distance to default 3.65 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $97.9M (short-term plus half of long-term), stock volatility 77.2%; Altman Z'' -2.68. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Total debt $233.4M against a stock market value of $1.68B.
Distance to default 3.65 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $97.9M (short-term plus half of long-term), stock volatility 77.2%; Altman Z'' -2.68. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Moderate
50
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$1.7B
52W Range9.82-21.451
Volume1,166,269
Avg Volume1,527,726
Beta0.99
Dividend—
Analyst Ratings
Company Info
CEOFrank Leonard
Employees1,605
SectorHealthcare
IndustryMedical - Devices
IPO Date2015-10-02
Websitenovocure.com
Neuhofstrasse 21
Baar 6340
CH
Baar 6340
CH
44 15 3475 6700
About Novocure Ltd
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. Its TTFields devices include Optune Gio, Optune Lua, and Optune Pax. The company also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Baar, Switzerland.
Latest News
NovoCure Limited $NVCR Stake Trimmed by Corient Private Wealth LP
Novocure Reports Patient Data Exposure in Cybersecurity Incident
NovoCure Limited $NVCR Holdings Reduced by Bank of America Corp DE
NovoCure drops as customer information leaked in cyberattack
Wall Street Analysts See a 50.86% Upside in NovoCure (NVCR): Can the Stock Really Move This High?
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Leonard Frank X | A-Award | 1,905 | $11.15 | 2026-06-30 |
| Ben Arye Barak | A-Award | 1,299 | $11.15 | 2026-06-30 |
| Danziger Asaf | A-Award | 268 | $11.15 | 2026-06-30 |
| Puri Michal Nath | A-Award | 1,905 | $11.15 | 2026-06-30 |
| Leonard Frank X | S-Sale | 34,273 | $17.93 | 2026-06-04 |